Provided by Tiger Trade Technology Pte. Ltd.

Atossa Genetics

2.44
+0.02000.83%
Post-market: 2.40-0.0400-1.64%19:36 EDT
Volume:265.61K
Turnover:652.05K
Market Cap:24.34M
PE:-0.56
High:2.74
Open:2.45
Low:2.12
Close:2.42
52wk High:18.00
52wk Low:1.70
Shares:9.97M
Float Shares:9.76M
Volume Ratio:4.39
T/O Rate:2.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3427
EPS(LYR):-4.0377
ROE:-89.23%
ROA:-50.69%
PB:0.91
PE(LYR):-0.60

Loading ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
13 hours ago

Atossa Therapeutics Staples CVRs to ATOS Shares Tied to Priority Review Voucher Proceeds

Reuters
·
Oct 09

Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value

THOMSON REUTERS
·
Oct 09

Atossa Therapeutics - CVR Holders Entitled to 25% of Net Proceeds, $50 Mln Aggregate Cap

THOMSON REUTERS
·
Oct 09

Atossa Therapeutics - Declares One Stapled CVR Per Share as of October 19, 2026

THOMSON REUTERS
·
Oct 09

US Research Roundup-Amrize, Dexcom, Lennar

Reuters
·
Oct 01

Atossa Therapeutics : Ascendiant Capital Markets Raises Target Price to $25 from $24

THOMSON REUTERS
·
Oct 01

Atossa Therapeutics Plans Stapled CVR Issuance Tied to Potential FDA Priority Review Voucher Proceeds

Reuters
·
Sep 29

Atossa Therapeutics - Shareholders to Receive One CVR Per Atos Share as of Record Date

THOMSON REUTERS
·
Sep 29

Atossa Therapeutics - Expects to File CVR Agreement with SEC Once Executed

THOMSON REUTERS
·
Sep 29

Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher

THOMSON REUTERS
·
Sep 29

Atossa Therapeutics - Cvrs Entitle Holders to 25% of Net Proceeds, Capped at $50 Mln

THOMSON REUTERS
·
Sep 29

Atossa Therapeutics CEO Steven Quay Joins ARDD 2026 Panel on Clinical Trials, Regulatory Pathways for Aging Diseases

Reuters
·
Sep 24

Atossa Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 10

Atossa Therapeutics Inc Expected to Post a Loss of $1.08 a Share - Earnings Preview

Reuters
·
Aug 07

Atossa Therapeutics Q2 Operating Income USD -8.7 Million

THOMSON REUTERS
·
Aug 07

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

THOMSON REUTERS
·
Aug 07

Atossa Therapeutics Q2 Net Loss Widens to $18.1 Million; Reports no Revenue

Reuters
·
Aug 07

Atossa Therapeutics sees opportunities for (Z)-endoxifen beyond breast cancer

TIPRANKS
·
Jul 31

Atossa Therapeutics’ (Z)-endoxifen compounds show anti-breast cancer action

TIPRANKS
·
Jul 28